China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)Yuankai Shi, Yu Huang, Yan Sun et al.|Asia-Pacific Journal of Clinical Oncology|2016Cited by 44
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label StudyShun Lü, Shucai Zhang, Dongqing Lv et al.|Journal of Thoracic Oncology|2022Cited by 25
First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).Yuankai Shi, Fenlai Tan, Lin Wang et al.|Journal of Clinical Oncology|2016Cited by 14
Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational studyYuequan Shi, Mengzhao Wang, Anwen Liu et al.|Chinese Medical Journal|2025Cited by 1